

## CORRIGENDUM

# Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

## Abstract

The authors wish to make the following corrections to their article: Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: from target population

characteristics to new formulations and post-marketing monitoring – a focus on the Italian system. *Drugs Context*. 2023;12:2023-2-6. <https://doi.org/10.7573/dic.2023-2-6>

## Corrigendum

The authors regret that there are errors in their original paper.

The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).

### Page 9, reference 38

38. Pharmacovigilance Risk Assessment Committee (PRAC). PRAC PSUR assessment report: Methadone, 12 January 2023, EMA/PRAC/12480/2023. [https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-january-2023\\_en.pdf](https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-9-12-january-2023_en.pdf). Accessed April 26, 2023. European Medicines Agency. Pharmacovigilance Risk Assessment Committee Periodic Safety Update Reports, Procedure No. PSUSA/00002004/202205 (EMA/PRAC/12480/2023). Data available on file.